AZ St-Lucas
Welcome,         Profile    Billing    Logout  
 1 Trial 
3 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Arts, Joris
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Completed
2
153
Europe, Canada, US
TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Takeda
Celiac Disease
11/24
11/24
NCT05780749: A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome

Completed
N/A
116
Europe
DDI-IBS-001, DDDI-IBS-001 placebo
Biokuris s.a.
Irritable Bowel Syndrome
02/25
02/25
Voorde, Lien Van De
THUNDER, NCT06282588: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Recruiting
2/3
493
Europe
Darolutamide, Nubeqa, BAY1841788, Darolutamide matched placebo, BAY1841788 matched placebo, Radiotherapy, Zoladex 3.6Mg Implant, Goserelin acetate 3.6 mg, Zoladex LA, Goserelin acetate 10.8 mg, Decapeptyl sustained release 22.5 mg, Triptorelin 11.25 mg, Decapeptyl sustained release 11.25 mg, Depo-Eligard 45 mg, Leuprorelin acetate 45 mg, Depo-Eligard 22.5 mg, Leuprorelin acetate 22.5 mg, Depo-Eligard 7.5 mg, Leuprorelin acetate 7.5 mg, Firmagon 120 MG Injection, Degarelix 40 mg, Firmagon 80 MG Injection, Degarelix 20 mg, Docetaxel, Taxotere
Cancer Research Antwerp, Bayer, Veracyte, Inc.
Prostate Cancer
07/30
12/30
Holvoet, Liesbeth
No trials found
Bellens, Koen
No trials found
Glorieux, Mary
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Arts, Joris
NCT05353985 / 2020-005438-14: A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Completed
2
153
Europe, Canada, US
TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Takeda
Celiac Disease
11/24
11/24
NCT05780749: A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome

Completed
N/A
116
Europe
DDI-IBS-001, DDDI-IBS-001 placebo
Biokuris s.a.
Irritable Bowel Syndrome
02/25
02/25
Voorde, Lien Van De
THUNDER, NCT06282588: Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers

Recruiting
2/3
493
Europe
Darolutamide, Nubeqa, BAY1841788, Darolutamide matched placebo, BAY1841788 matched placebo, Radiotherapy, Zoladex 3.6Mg Implant, Goserelin acetate 3.6 mg, Zoladex LA, Goserelin acetate 10.8 mg, Decapeptyl sustained release 22.5 mg, Triptorelin 11.25 mg, Decapeptyl sustained release 11.25 mg, Depo-Eligard 45 mg, Leuprorelin acetate 45 mg, Depo-Eligard 22.5 mg, Leuprorelin acetate 22.5 mg, Depo-Eligard 7.5 mg, Leuprorelin acetate 7.5 mg, Firmagon 120 MG Injection, Degarelix 40 mg, Firmagon 80 MG Injection, Degarelix 20 mg, Docetaxel, Taxotere
Cancer Research Antwerp, Bayer, Veracyte, Inc.
Prostate Cancer
07/30
12/30
Holvoet, Liesbeth
No trials found
Bellens, Koen
No trials found
Glorieux, Mary
No trials found

Download Options